Study of drug combinations for operable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests different combinations of the immunotherapy cemiplimab and chemotherapy for people with stage II to IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if adding other treatments helps more than the standard approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II to IIIB non-small cell lung cancer that the doctor believes can be removed with surgery.
- You have not had any chemotherapy or radiation for this current lung cancer.
- Your tumor does not have certain gene changes (EGFR or ALK).
- You are well enough to be up and about (ECOG score 0 or 1).
- Your heart, kidneys, liver, and bone marrow are working well enough as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This trial tests a combination of SYS6010 and an immunotherapy drug (anti-PD-(L)-1) given after surgery to prevent non-small cell lung cancer from coming back. It's for people whose cancer was removed but didn't shrink much with prior treatment before surgery.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.